Aura Biosciences, Inc. AURA
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2021 · data as of November 13, 2026
Aura Biosciences, Inc. (AURA) is a healthcare company listed in the US with a market value of about $740M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -35%.
About Aura Biosciences
Aura Biosciences is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2021. It was profitable in 0 of the last 6 years in our data. Its share count rose by 102% over three years (dilution for shareholders).
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Net income | -$106M | -$87M | -$76M | -$59M | -$35M | -$22M |
| Free cash flow | -$85M | -$81M | -$65M | -$56M | -$35M | -$25M |
| EPS (diluted) | $-1.76 | $-1.75 | $-1.93 | $-1.96 | $-8.95 | $-82.06 |
| Net margin | — | — | — | — | — | — |
| ROIC | -57.8% | -44.5% | -27.4% | -27.9% | -18.2% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 5 analysts is $16.60, 133% above the current price; targets range from $12.00 to $23.00; the consensus rating is “Strong buy”; expected EPS is $-1.50 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Aura Biosciences pay a dividend?
Not currently.
Is Aura Biosciences a good stock to buy?
We do not give buy or sell advice. Aura Biosciences scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.